Search for: "Sanofi Aventis"
Results 1 - 20 of 206
Sorted by Relevance | Sort by Date
19 Feb, 2008 1:23 am
... Thus, because Safety Syringes has asserted claims of inducement and contributory patent infringement in the Plastef case, Sanofi-Aventis believes that it is being accused of infringing the three patents and that an actual controversy
exists between the parties. Sanofi ... of pursuing behavior that [Safety Syringes] would allege constitutes an infringement or of abandoning a
course of action which Aventis believes it has a lawful right to pursue." PRACTICE NOTE: Sending a cease and desist letter to a ...
29 Sep 5:05 am
... Holds Plaintiffs filed a putative class action against French pharmaceutical company Sanofi-Aventis and certain individual defendants alleging violations of the Securities Exchange Act ... drug called 'rimonabant' used to treat obesity and related
illnesses." In re Sanofi-Aventis Sec. Litig., ___ F.Supp.2d ___ (S.D. ... allegations underlying the
class action complaint, during the approval process the FDA sent Sanofi an approval letter for the drug's use in connection with obesity, but a
non-approval ...
14 Nov, 2006 3:03 pm
... 's benefits are outweighed by its distinct risk of serious side effects. According to the November 14, 2006 AP article: Sanofi-Aventis welcomes the opportunity to discuss Ketek, company spokeswoman Lisa Kennedy said. "Based on the data
... FDA advisory panel is being convened next month to discuss Ketek seemingly could not come at a worse time for Sanofi-Aventis. The Senate Finance Committee is investigating how Ketek was approved by the FDA in the first place. This Senate investigation is looking ...
26 Mar, 2007 2:53 pm
... the FDA announced that a so-called "Dear Doctor" letter regarding the antibiotic Ketek (telithromycin) has been sent by Sanofi-Aventis to healthcare professionals alerting them to new safety information for Ketek. As one may recall, in
mid-February 2007 the ... the risks of Ketek and how to use this antibiotic safely. To our knowledge, no explanation was issued by the FDA nor Sanofi-Aventis about why there was an apparent six-week delay in sending out this March 2007 Dear Doctor letter
regarding the ...
9 Feb, 2007 11:37 am
By Christopher P. Singer In a February 9, 2007 press release, Sanofi-Aventis announced that it has
lost its patent infringement suit against generic drugmakers Amphastar Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd., filed in the U.S. District Court for the Central
District of California. The suit relates to Sanofi-Aventis' blockbuster...
12 Feb, 2007 11:12 am
... Get Black-box Warning And Medication Guide For Patients, Also (Posted by Tom Lamb at DrugInjuryWatch.com) In mid-December 2006 an FDA advisory panel recommended that any future use
of the antibiotic Ketek should be restricted. Specifically, the panel members recommended that Sanofi-Aventis SA's antibiotic Ketek be prescribed for community-acquired pneumonia, only, and should no longer be used as treatment for acute bacterial ...
15 Apr 11:37 am
European pharmaceutical giant Sanofi-Aventis continued its buying spree by acquiring privately owned
U.S. biopharmaceutical company BiPar Sciences on Wednesday. O'Melveny advised BiPar and Sanofi tapped Jones Day for the deal.
10 Sep 9:59 pm
... Circuit demonstrated once again the quagmire that can exist when lower courts attempt to apply the CAFC's rather quixotic jurisprudence on claim construction. The case,
Sanofi-Aventis U.S. LLC v. Sandoz, Inc.(1), arose as the result of ANDA filings by several Defendants
for oxaliplatin, the active ingredient in Sanofi's Eloxatin® colorectal cancer drug. Two claims of the patent at issue, U.S. Patent No.
5,338,874, were asserted against the ...
19 Feb, 2007 8:22 pm
On February 9, 2007, Sanofi-aventis lost in its patent infringement suit against Amphastar and Teva
at the U.S. District Court for the Central District of California. The pharmaceutical giant brought suit against Amphastar and Teva, generic pharmaceutical companies, to stop them from
producing a generic version of their blockbuster drug, Lovenox. Lovenox, is an anticoagulant, and [...]
31 May, 2007 9:31 pm
By Christopher P. Singer -- In a May 29, 2007 press release, sanofi-aventis and UCB announced that
the FDA approved Xyzal® (active ingredient: levocetirizine dihydrochloride) a once-daily prescription antihistamine for the relief of seasonal and perennial allergic rhinitis, as well
as for the treatment of chronic idiopathic urticaria (hives) in...
17 Oct, 2008 8:57 am
Devenish Nutrition Ltd v Sanofi-Aventis SA (France) and others [2008] EWCA Civ 1086; [2008] WLR (D)
317 "An account of profits could not be awarded on a claim for a non-proprietary tort. Community law neither prevented nor required the recognition in domestic law of a restitutionary
award as a remedy for breach of statutory duty." WLR Daily, 16th October 2008 Source: www.lawreports.co.uk Please note once a case has been fully reported in one of the ICLR series the
...
4 Nov, 2008 9:39 am
Devenish Nutrition Ltd v Sanofi-Aventis SA (France) and Others Court of Appeal "An account of profits
could not be awarded on a claim for a nonproprietary tort." The Times, 4th November 2008 Source: www.timesonline.co.uk Please note the Times Law Reports are only available free on Times
Online for 21 days from the date of publication.
19 Jun, 2007 8:21 am
... Following a month-long trial held earlier this year, in an opinion released today a federal district court upheld the validity of Sanofi's
U.S. Patent No. 4,847,265. The '265 patent covers clopidogrel bisulfate, the active ... Apotex from infringing the '265 patent and stated that damages will be set in future proceedings.
At trial, Apotex argued that a prior Aventis patent had inherently anticipated clopidogrel bisulfate ("CBS"). The earlier patent disclosed a
broad genus of thienopyridines which ...
10 Sep 4:53 pm
The appellate ruling comes too late to keep generic manufacturers of the colon cancer drug Eloxatin out of the market, but the Federal Circuit found that a lower court judge interpreted
Sanofi's patent incorrectly when he cleared the way for its rivals.
11 Feb, 2007 8:27 pm
... R. Pfaelzer of the U.S. District Court for the Central District of California held Aventis's U.S. Patent No. 5,389,618 and its U.S ...
polysaccharides that is difficult to characterize and may be impossible for generic companies to replicate. Indeed, Aventis filed a citizen
petition in 2003 urging the FDA not to approve generic versions ... 9 Forbes article, reporting that Momenta Pharmaceuticals may have the best chance of obtaining FDA approval for
generic Lovenox Feb. 9 Sanofi-Aventis press release
15 Aug, 2006 6:45 am
... agreed to delay selling its drug in return for a minimum of $40-million from Bristol and Sanofi. In return, Apotex would be allowed to
introduce its version of Plavix before the patent expired ... then lost the patent suit. Under the revised settlement agreement, Bristol and Sanofi could collect damages limited to 40-50% of Apotex's net sales ... Launch Generic Plavix At Its Own Risk FTC Rejects Patent Deal by Bristol-Myers and
Sanofi Does Sanofi-Aventis Patent Settlement With Apotex
Reveal a Trend?
12 Sep, 2007 9:48 am
... Monday, the U.S. Department of Justice announced that Aventis Pharmaceuticals (now known as sanofi-aventis U.S. Inc. and sanofi-aventis U.S. LLC.) paid the United States and several individual states over $190 million to settle allegations of false Medicare claims and alleged
fraudulent pricing ... and fraudulent prices for Anzemet based upon the company's knowledge of federal reimbursement rates. Aventis charged one
price to federal programs, and another lower price to customers. A ...
18 Jul, 2007 8:41 am
Forbes reports "Sanofi-Aventis said it will 'vigorously' defend its rights to ensure the availability
of its products after Danish drug company Novo Nordisk said it is suing the French pharmaceutical group over patent infrigement relating to Solostar, ... -delivery pen." In the federal
court system, service of a complaint can occur well after the filing of the complaint. Forbes noted: "Sanofi-Aventis has not yet been served with a complaint by Novo and our understanding of Novo's allegation is very ...
8 Aug, 2008 3:01 pm
... Nordisk A/S wasn't getting a preliminary injunction out of Sanofi-Aventis after alleging that
Sanofi's SoloStar product infringed claims of Novo's U.S. Patent No. 7,241,278. Novo Nordisk A/S v. Sanofi-Aventis (08-1225). In order to obtain a preliminary injunction, a patentee must show ... Novo failed to show
a reasonable likelihood of success on the merits. The district court reasoned that Sanofi "raised substantial questions regarding whether the
specification read as a whole suggests that the very ...
24 May 10:58 pm
... relevant documents should play a substantial role in the venue analysis is somewhat antiquated in the era of electronic storage and transmission." Sanofi-Aventis, slip op. at 11. (...) Finally, we note that the court's antiquated era argument was essentially
rejected in ... trial is lower in the Eastern District - 18.4 months - than in the Northern District - 25.5 months. Sanofi also points to a
2008 patent litigation study, which found that in the twenty most active patent districts in the country ...
Search on: Blawgs.FM | BlawgSearch Google Co-op | Blawg.com | Bloglines | Feedster | Google Blog Search | Technorati | Google | MSN | Yahoo!